drugset / Trial / NCT06339619
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy.
Timeline
- Start
- 2024-03-11
- Primary completion
- 2028-03-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | Tegafur | Unknown | 40 mg | Oral |
| Subject | Tegafur | Unknown | 50 mg | Oral |
| Subject | Tegafur | Unknown | 60 mg | Oral |